We recognize the groundbreaking innovations emerging from biotech and pharmaceutical companies every day and understand the critical impact of a successful clinical trial. At Condor, our mission is to empower organizations with the technology, financial intelligence, and accurate data needed to drive operational excellence and accelerate therapeutic advancements.
Our CEO began her career as a CPA and auditor at Ernst & Young, gaining a strong foundation in financial integrity and compliance. She later transitioned into finance and operations leadership roles within biotech and pharmaceutical organizations, where she tackled the complexities of clinical financial management firsthand. This on-the-ground experience shaped Condor’s mission—to deliver purpose-built financial solutions that drive efficiency, accuracy, and strategic decision-making for the industry.
At Condor, we are driven by a singular mission—to make life-saving treatments more accessible by empowering the innovators behind clinical advancements.
During her tenure at biotech and pharma organizations, Jen Kyle witnessed firsthand the profound impact of clinical trials on patients, including her own family and loved ones. This experience solidified her commitment to supporting the organizations driving medical breakthroughs.
To turn this vision into reality, she partnered with industry leaders to assemble a world-class team, developing a cutting-edge, enterprise-grade financial intelligence platform. Condor eliminates the inefficiencies that cost the industry billions due to fragmented financial processes, disparate systems, disconnected teams and operational bottlenecks. By bridging this gap, we enable organizations to focus on what truly matters—bringing transformative therapies to patients faster.